#China #Shanghai #CAR-T therapy #Satri-cel #Jiahui International

Groundbreaking CAR-T Therapy for Solid Tumors

In a significant development within the field of oncology, Jiahui International Cancer Center (JICC) has recently secured approval for Satri-cel (CT041, Kaileimei®), the world's first CAR-T cell therapy designated for use against solid tumors. This landmark achievement is expected to change the landscape of cancer treatment, providing new options for patients diagnosed with advanced gastric cancer.

Approved by China's National Medical Products Administration (NMPA), this innovative therapy is specifically intended for patients suffering from Claudin18.2-positive and HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma who have already undergone at least two prior lines of treatment without success.

Jiahui International Cancer Center is not just another treatment facility; it has emerged as a leading hub for advanced oncology care in China, providing essential access to pioneering treatment options for both domestic and international patients. The center's multidisciplinary cancer program ensures that eligible patients can now benefit from Satri-cel, thanks to its comprehensive approach and dedicated international patient services.

In light of the growing interest in cutting-edge cancer therapies available in China, JICC has been actively treating CAR-T patients from an array of countries and regions. The approval of this first solid tumor CAR-T therapy is anticipated to further spur global demand for access to China's rapidly evolving advancements in oncology.

Dr. Linli Xuan, Chief of Medical Oncology at JICC, expressed the importance of this milestone, saying, "Satri-cel's approval marks a historic achievement for patients and the global oncology community at large. The successful application of CAR-T therapy within solid tumors has long presented a formidable challenge in cancer medicine. This groundbreaking advancement provides renewed hope for individuals battling advanced gastric cancer and emphasizes China's increasing contribution in the issuance of transformative cancer treatments. At Jiahui International Cancer Center, our mission is to facilitate access to these medical breakthroughs for patients worldwide through specialized multidisciplinary care and tailored international support services."

JICC encompasses a wide array of oncology services, including medical oncology, surgical oncology, radiation oncology, precision medicine, and advanced cellular therapies. By offering specialist consultations, multilingual coordination, and efficient care pathways, the center helps connect patients globally to the most recent innovations in cancer treatment.

In conclusion, the approval of Satri-cel represents a promising new avenue in cancer treatment, signifying a leap forward in the application of CAR-T therapy for solid tumors. Patients can now look forward to improved therapeutic options thanks to the dedicated efforts of organizations like the Jiahui International Cancer Center. For anybody interested in learning more or looking to access these advances, JICC is readily available to offer assistance and information through various channels, including email and WhatsApp.

For further engagement or inquiries related to international patient access, potential patients and healthcare professionals can reach out to Jiahui International Cancer Center via email or WhatsApp for dedicated support and guidance.